Approval Delays For Standard NMEs Caused Primarily By “Safety Issues” – FDA
Executive Summary
FDA is citing "safety issues" as the primary reason for approval delays for standard new molecular entities in 2000 and 2001 in its 12002 Report to the Nation
You may also be interested in...
Manufacturing Reviews In Second-Cycle NDAs To Be Streamlined In FDA Pilot
FDA hopes to streamline chemistry, manufacturing and controls review in resubmitted NDAs and supplemental applications through several pilot programs
Manufacturing Reviews In Second-Cycle NDAs To Be Streamlined In FDA Pilot
FDA hopes to streamline chemistry, manufacturing and controls review in resubmitted NDAs and supplemental applications through several pilot programs
FDA Approves 9 NMEs, 6 BLAs In First Half ‘03, On Track To Exceed 2002 Total
FDA closed out the first half of 2003 with nine new molecular entities and six major biologic approvals, putting the agency well ahead of where it was at the same time last year, according to an analysis by F-D-C Reports' Pharmaceutical Approvals Monthly